A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.

NCT03103724 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma Prostate

Interventions

DRUG: Xtandi

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano